[go: up one dir, main page]

NO2006002I1 - Posakonzol eventuelt i form av en ester og/eller et farmasoytisk akseptabelt salt derav (se kopi frausp dictionary med strukturformel) - Google Patents

Posakonzol eventuelt i form av en ester og/eller et farmasoytisk akseptabelt salt derav (se kopi frausp dictionary med strukturformel)

Info

Publication number
NO2006002I1
NO2006002I1 NO2006002C NO2006002C NO2006002I1 NO 2006002 I1 NO2006002 I1 NO 2006002I1 NO 2006002 C NO2006002 C NO 2006002C NO 2006002 C NO2006002 C NO 2006002C NO 2006002 I1 NO2006002 I1 NO 2006002I1
Authority
NO
Norway
Prior art keywords
ester
pharmaceutically acceptable
acceptable salt
posaconzole
optionally
Prior art date
Application number
NO2006002C
Other languages
English (en)
Other versions
NO2006002I2 (no
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22622452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2006002(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO2006002I1 publication Critical patent/NO2006002I1/no
Publication of NO2006002I2 publication Critical patent/NO2006002I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
NO2006002C 1993-12-21 2006-02-10 Posakonazol eventuelt i form av en ester og/eller et farmasøytisk akseptabelt salt derav. NO2006002I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17108393A 1993-12-21 1993-12-21
PCT/US1994/014236 WO1995017407A1 (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Publications (2)

Publication Number Publication Date
NO2006002I1 true NO2006002I1 (no) 2006-02-20
NO2006002I2 NO2006002I2 (no) 2011-03-07

Family

ID=22622452

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19962616A NO316173B1 (no) 1993-12-21 1996-06-20 Tetrahydrofuran-antifungale midler
NO2006002C NO2006002I2 (no) 1993-12-21 2006-02-10 Posakonazol eventuelt i form av en ester og/eller et farmasøytisk akseptabelt salt derav.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19962616A NO316173B1 (no) 1993-12-21 1996-06-20 Tetrahydrofuran-antifungale midler

Country Status (29)

Country Link
EP (1) EP0736030B1 (no)
JP (1) JP2834889B2 (no)
KR (1) KR0179990B1 (no)
CN (1) CN1064685C (no)
AT (1) ATE204875T1 (no)
AU (1) AU681753B2 (no)
BR (1) BR1100154B1 (no)
CA (1) CA2179396C (no)
CO (1) CO4520281A1 (no)
CZ (1) CZ294823B6 (no)
DE (2) DE122006000004I2 (no)
DK (1) DK0736030T3 (no)
ES (1) ES2159623T3 (no)
FI (1) FI118470B (no)
FR (1) FR06C0009I2 (no)
HK (1) HK1008820A1 (no)
HU (1) HU225062B1 (no)
IL (1) IL112081A (no)
LU (1) LU91216I2 (no)
MY (1) MY130217A (no)
NL (1) NL300219I2 (no)
NO (2) NO316173B1 (no)
NZ (1) NZ278713A (no)
PL (1) PL181193B1 (no)
PT (1) PT736030E (no)
SK (1) SK283035B6 (no)
TW (1) TW377349B (no)
WO (1) WO1995017407A1 (no)
ZA (1) ZA9410142B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186540T1 (de) * 1994-01-24 1999-11-15 Janssen Pharmaceutica Nv Wasserlösliche azol-antifungus
WO1996038443A1 (en) * 1995-06-02 1996-12-05 Schering Corporation Tetrahydrofuran antifungals
ATE247108T1 (de) * 1995-06-19 2003-08-15 Schering Corp Antifungale tetrahydrofurane
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
KR20000064469A (ko) * 1995-12-20 2000-11-06 둘락 노먼 씨. 하이드라지드의제조방법
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
CN1121860C (zh) * 1996-05-24 2003-09-24 先灵公司 提高生物利用度的抗真菌组合物
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
CN1228693A (zh) * 1996-06-28 1999-09-15 先灵公司 含有三唑类抗真菌化合物的口服组合物
CA2269608A1 (en) * 1996-11-12 1998-05-22 Sepracor Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
CA2269616A1 (en) * 1996-11-12 1998-05-22 Gerald J. Tanoury 2r,4s,s,r- and 2s,4r,s,r-hydroxyitraconazole
CN1237173A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,r,r－和2s,4r,r,r－羟基伊曲康唑
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
US5684197A (en) * 1996-12-12 1997-11-04 Schering Corporation Process for preparation of hydrazides
BR9809744A (pt) * 1997-02-11 2000-06-20 Janssen Pharmaceutica Nv Antifúngicos de azol contendo éster de aminoácido
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
TR200000753T2 (tr) * 1997-09-25 2001-01-22 Schering Corporation Mukabil antifungal ajan için prodrog olarak tetrahidrofuran fosfat ve hidroksi esterleri.
DE69822859T2 (de) * 1997-10-07 2005-01-27 Schering Corp. Krytallinischer fungizider polymorph
WO1999018111A1 (en) * 1997-10-07 1999-04-15 Schering Corporation Crystalline antifungal glycine ester polymorph
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
EA200101172A1 (ru) * 1999-05-04 2002-04-25 Янссен Фармацевтика Н.В. Противогрибковые эфиры
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
MXPA03009021A (es) * 2001-04-03 2004-02-12 Schering Corp Composicion antifungal con biodisponibilidad aumentada.
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
EP1511490A4 (en) 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
CN100360117C (zh) 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ITMI20032020A1 (it) 2003-10-17 2005-04-18 Italfarmaco Spa Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
WO2006020689A1 (en) * 2004-08-13 2006-02-23 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
EP2451805A1 (en) 2009-07-09 2012-05-16 Sandoz AG A crystalline form of posaconazole
WO2011158248A2 (en) * 2010-05-12 2011-12-22 Glenmark Generics Limited Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
CA2798002C (en) * 2010-05-19 2019-12-03 Sandoz Ag Process for the preparation of chiral triazolones
RU2588570C2 (ru) * 2010-05-19 2016-07-10 Сандоз Аг Способ получения хиральных гидразидов
MX2012013331A (es) 2010-05-19 2013-02-01 Sandoz Ag Purificacion de posaconazol y de intermediarios de posaconazol.
CN102892762B (zh) * 2010-05-19 2016-04-20 桑多斯股份公司 制备泊沙康唑中间体
DK3391890T3 (da) 2010-06-29 2021-11-01 Merck Sharp & Dohme Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin
US9493428B2 (en) 2011-06-16 2016-11-15 Sandoz Ag Process for the preparation of a chiral compound
EP2789610A1 (en) 2013-04-10 2014-10-15 Sandoz Ag Purification of Posaconazole Intermediates
WO2015011224A1 (en) * 2013-07-25 2015-01-29 Sandoz Ag Improved process for the preparation of crystalline form iv of posaconazole
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
WO2016087878A1 (en) 2014-12-05 2016-06-09 Pulmocide Limited Antimycotic compound
CN107635988B (zh) * 2015-05-21 2021-06-18 普尔莫赛德有限公司 抗真菌的苯甲酰胺类衍生物或其可药用盐
CN106317032A (zh) * 2015-06-15 2017-01-11 重庆圣华曦药业股份有限公司 一种制备高纯度的泊沙康唑的方法
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
JP7054381B2 (ja) * 2015-09-23 2022-04-13 バイオコン・リミテッド 結晶形態のポサコナゾール中間体および非晶質ポサコナゾールの調製のためのプロセス
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
US11185548B2 (en) 2016-12-23 2021-11-30 Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN106967054A (zh) * 2017-03-30 2017-07-21 成都绿林科技有限公司 一种泊沙康唑的制备方法
CN106883221A (zh) * 2017-04-17 2017-06-23 兰州大学 一种无定形泊沙康唑及其制备方法
CN108341754A (zh) * 2018-03-12 2018-07-31 扬子江药业集团有限公司 泊沙康唑杂质及其制备方法和用途
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN112778369B (zh) * 2019-11-05 2024-01-26 华创合成制药股份有限公司 一种三唑类衍生物及其制备方法和用途
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
EP0386143A1 (en) * 1987-11-20 1990-09-12 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) * 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals

Also Published As

Publication number Publication date
EP0736030A1 (en) 1996-10-09
MY130217A (en) 2007-06-29
DE122006000004I1 (de) 2006-04-27
BR1100154B1 (pt) 2013-11-26
DE122006000004I2 (de) 2007-03-29
DE69428125T2 (de) 2002-05-02
JP2834889B2 (ja) 1998-12-14
FI118470B (fi) 2007-11-30
ES2159623T3 (es) 2001-10-16
SK283035B6 (sk) 2003-02-04
NL300219I1 (nl) 2006-04-03
CO4520281A1 (es) 1997-10-15
FI962577A0 (fi) 1996-06-20
NO2006002I2 (no) 2011-03-07
AU1512795A (en) 1995-07-10
FR06C0009I1 (no) 2006-05-19
IL112081A (en) 2001-08-26
CA2179396C (en) 2001-04-17
HK1008820A1 (en) 1999-05-21
WO1995017407A1 (en) 1995-06-29
FR06C0009I2 (no) 2006-12-29
KR0179990B1 (en) 1999-03-20
ZA9410142B (en) 1996-05-02
SK82696A3 (en) 1997-03-05
NO316173B1 (no) 2003-12-22
NO962616D0 (no) 1996-06-20
CZ294823B6 (cs) 2005-03-16
TW377349B (en) 1999-12-21
DE69428125D1 (de) 2001-10-04
NO962616L (no) 1996-08-07
HUT75879A (en) 1997-05-28
FI962577L (fi) 1996-06-20
LU91216I2 (en) 2006-03-27
HU225062B1 (en) 2006-05-29
DK0736030T3 (da) 2001-10-29
PL315169A1 (en) 1996-10-14
CA2179396A1 (en) 1995-06-29
HU9601709D0 (en) 1996-08-28
NL300219I2 (nl) 2006-05-01
JPH09500658A (ja) 1997-01-21
CN1064685C (zh) 2001-04-18
EP0736030B1 (en) 2001-08-29
ATE204875T1 (de) 2001-09-15
PL181193B1 (pl) 2001-06-29
CN1142828A (zh) 1997-02-12
CZ180596A3 (en) 1997-01-15
PT736030E (pt) 2002-01-30
NZ278713A (en) 1997-12-19
IL112081A0 (en) 1995-03-15
AU681753B2 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
NO2006002I1 (no) Posakonzol eventuelt i form av en ester og/eller et farmasoytisk akseptabelt salt derav (se kopi frausp dictionary med strukturformel)
MX9701229A (es) Antifungicos de tetrahidrofurano.
EA199600104A1 (ru) Повышенная биодоступность биологически активных соединений при связывании с производными полипирролкарбоксамидонафталиновой кислоты
CA2150287A1 (en) Agent for treating hepato-biliary diseases
ES8404361A1 (es) Un procedimiento para la preparacion de un derivado de cefalosporina.
DE69629474D1 (de) Antifungale tetrahydrofurane
IT1140998B (it) Sali di endo-8-metil-8-sin-alchil-8-azoniabiciclo aperta par. quadrata 3.2.1. chiusa par. quadrata-ottan-3-alchilcarbossilati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
FI961423A0 (fi) Antrasykliinidisakkaridit, menetelmä niiden valmistamiseksi sekä niitä sisältävät farmaseuttiset koostumukset
ATE1900T1 (de) Alpha-aethinyl-alpha-aminosaeuren und deren ester sowie sie enthaltende pharmazeutische zusammensetzungen.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
AR003437A1 (es) Un compuesto antifungico de tetrahidrofurano, una composicion farmaceutica que los contiene, su uso para preparar un medicamento antifungico y una sal deester aminoacido del mismo
FI922518A (fi) Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi
FI921681A (fi) Menetelmä lääkeaineina käyttökelpoisten 2-(heterosyklyylitio)karbapeneemijohdannaisten valmistamiseksi
CO4770982A1 (es) Nuevas formulaciones